公开(公告)号：US20110109651A1

公开(公告)日：2011-05-12

申请号：US13002029

申请日：2009-06-15

申请人： David Fairlamb ,  Mark William James Ferguson ,  Tracey Mason ,  Sharon O'Kane ,  Ann Helena Ledwith

发明人： David Fairlamb ,  Mark William James Ferguson ,  Tracey Mason ,  Sharon O'Kane ,  Ann Helena Ledwith

IPC分类号： G06T7/00 ,  G09G5/00

CPC分类号： G06T7/0014 ,  G06F19/321 ,  G06T2207/20021 ,  G06T2207/30088 ,  G16H10/20 ,  G16H40/63

摘要： A method and apparatus for determining the efficacy of a medicament for the treatment of wounds or scars. The method comprises selecting first and second scarring site portions wherein said first scarring site portion has been treated with said medicament. A pair of images comprising a first image of said first scarring site portion and a second image of said second scarring site portion is generated, and the pair of images is displayed. A recording element comprising first and second recording portions is provided, wherein said first recording portion comprises a plurality of first points indicating that scarring in said first image is less severe than scarring in said second image, and said second recording portion comprises a plurality of second points indicating that scarring in said second image is less severe than scarring in said first image, each of said first and second points having different associated values. Data identifying one of said points is received and used to determine the efficacy of said medicament.

摘要翻译： 用于确定用于治疗伤口或瘢痕的药物的功效的方法和装置。 该方法包括选择第一和第二瘢痕形成部位，其中所述第一瘢痕形成部位已用所述药物处理。 产生包括所述第一瘢痕形成部位的第一图像和所述第二瘢痕形成部位的第二图像的一对图像，并且显示所述一对图像。 提供了包括第一和第二记录部分的记录元件，其中所述第一记录部分包括多个第一点，其指示所述第一图像中的瘢痕形成不如所述第二图像中的瘢痕形成严重，并且所述第二记录部分包括多个第二 指示所述第二图像中的瘢痕形成比所述第一图像中的瘢痕形成严重的点，所述第一和第二点中的每一个具有不同的相关联的值。 接收识别所述点之一的数据并用于确定所述药物的功效。

公开(公告)号：US20110152189A1

公开(公告)日：2011-06-23

申请号：US13003755

申请日：2008-12-11

申请人： Mark William James Ferguson ,  Sharon O'Kane ,  Tracey Mason ,  Mark Cooper ,  Nick Occleston ,  David Fairlamb ,  James Bush

发明人： Mark William James Ferguson ,  Sharon O'Kane ,  Tracey Mason ,  Mark Cooper ,  Nick Occleston ,  David Fairlamb ,  James Bush

IPC分类号： A61K38/18 ,  A61P17/02

CPC分类号： A61K38/1841 ,  A61K9/0019 ,  A61K9/0021 ,  A61K38/00

摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

摘要翻译： 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在第一次治疗发生率中，每厘米的伤口边缘或要形成伤口的部位的每厘米处提供约350ng至1000ng的TGF-β1; 并且在第一次治疗发生后，在伤口形成之后发生，并且在第一次治疗后8至48小时之间，所述伤口被提供有大约350ng和1000ng之间的TGF-和bgr 3 伤口边缘的厘米，其中瘢痕形成被抑制。 所提供的TGF-β1的量可以在每次治疗发生率中相同。 在每次治疗发生率中每厘米提供的TGF-β1,3的量优选为约500ng。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。